Key result
Prolonged release verapamil demonstrated high efficiency and safety in patients with arterial hypertension and comorbidities, and proved advantageous for supraventricular arrhythmias.
Why the study?
Does prolonged release verapamil improve outcomes in patients with arterial hypertension and supraventricular arrhythmias?
Does prolonged release verapamil improve outcomes in patients with arterial hypertension and supraventricular arrhythmias?
Prolonged release verapamil is an effective and safe treatment for hypertension and supraventricular arrhythmias, even in the presence of comorbidities like ischemic heart disease and COPD.
May support verapamil in hypertensive patients with supraventricular arrhythmias and comorbidities; leaves open confirmation in randomized trials.
The review shows the results of the use of prolonged release verapamil (Isoptin® SR) in clinical practice. Numerous randomized clinical studies confirm the high efficiency and safety of Isoptin® SR in patients with arterial hypertension, as well as in patients with arterial hypertension in combination with ischaemic heart disease, chronic obstructive pulmonary diseasesand disorders of carbohydrate and lipid metabolism. The advantage of Isoptin® SR (verapamil) application in case of supraventricular arrhythmias has been proven.
No takes yet. Share an insight, caveat, or question.
Gaponova et al. (2016) conducted a review in Arterial hypertension and supraventricular arrhythmias. Prolonged release verapamil (Isoptin® SR) was evaluated. Prolonged release verapamil demonstrated high efficiency and safety in patients with arterial hypertension and comorbidities, and proved advantageous for supraventricular arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: